{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:41:29Z","timestamp":1792737689569,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejradiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejrad.2026.113213","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:10:48Z","timestamp":1788480648000},"page":"113213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Laying the groundwork for future health economic evaluation of [18F]PSMA PET\/CT in guiding treatment decisions for metastatic castration-resistant prostate cancer patients"],"prefix":"10.1016","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2313-0337","authenticated-orcid":false,"given":"S.","family":"van Mossel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.J.M.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Kleiburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"van der Hulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Koffijberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.P.","family":"Kuppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Saing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.F.","family":"de Geus-Oei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Heijmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejrad.2026.113213_b0005","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2026.113213_b0010","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2026.113213_b0015","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejrad.2026.113213_b0020","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2026.113213_b0025","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2026.113213_b0030","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2026.113213_b0035","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejrad.2026.113213_b0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2026.113213_b0045","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ejrad.2026.113213_b0050","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2026.113213_b0055","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejrad.2026.113213_b0060","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejrad.2026.113213_b0065","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejrad.2026.113213_b0070","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41391-021-00344-1","article-title":"The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population","volume":"24","author":"Westgeest","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ejrad.2026.113213_b0075","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.euf.2016.09.008","article-title":"Differences in trial and real-world populations in the dutch castration-resistant prostate cancer registry","volume":"4","author":"Westgeest","year":"2018","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.ejrad.2026.113213_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2024.111774","article-title":"PSMA PET\/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients","volume":"181","author":"Kleiburg","year":"2024","journal-title":"Eur. J. Radiol."},{"key":"10.1016\/j.ejrad.2026.113213_b0085","doi-asserted-by":"crossref","first-page":"786","DOI":"10.2967\/jnumed.118.219501","article-title":"Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology","volume":"60","author":"Hope","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejrad.2026.113213_b0090","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.ejrad.2026.113213_b0095","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2967\/jnumed.123.266654","article-title":"The impact of baseline PSMA PET\/CT versus CT on outcomes of 223Ra therapy in metastatic castration-resistant prostate cancer patients","volume":"65","author":"Bosch","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejrad.2026.113213_b0100","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The lancet commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejrad.2026.113213_b0105","doi-asserted-by":"crossref","unstructured":"S. Gillessen, G. Attard, T.M. Beer, H. Beltran, A. Bjartell, A. Bossi, A. Briganti, R.G. Bristow, K.N. Chi, N. Clarke, I.D. Davis, J. de Bono, C.G. Drake, I. Duran, R. Eeles, E. Efstathiou, C.P. Evans, S. Fanti, F.Y. Feng, K. Fizazi, M. Frydenberg, M. Gleave, S. Halabi, A. Heidenreich, D. Heinrich, C. (Tia) S. Higano, M.S. Hofman, M. Hussain, N. James, R. Kanesvaran, P. Kantoff, R.B. Khauli, R. Leibowitz, C. Logothetis, F. Maluf, R. Millman, A.K. Morgans, M.J. Morris, N. Mottet, H. Mrabti, D.G. Murphy, V. Murthy, W.K. Oh, P. Ost, J.M. O\u2019Sullivan, A.R. Padhani, C. Parker, D.M.C. Poon, C.C. Pritchard, R.E. Reiter, M. Roach, M. Rubin, C.J. Ryan, F. Saad, J.P. Sade, O. Sartor, H.I. Scher, N. Shore, E. Small, M. Smith, H. Soule, C.N. Sternberg, T. Steuber, H. Suzuki, C. Sweeney, M.R. Sydes, M.E. Taplin, B. Tombal, L. T\u00fcrkeri, I. van Oort, A. Zapatero, A. Omlin, Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019, in: Eur. Urol., Elsevier B.V., 2020: pp. 508\u2013547. https:\/\/doi.org\/10.1016\/j.eururo.2020.01.012.","DOI":"10.1016\/j.eururo.2020.01.012"},{"key":"10.1016\/j.ejrad.2026.113213_b0110","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ejrad.2026.113213_b0115","unstructured":"National Health Care Institute, Dutch dbc-information system, Https:\/\/Www.Opendisdata.Nl. Accessed August 25 (2023)."},{"key":"10.1016\/j.ejrad.2026.113213_b0120","unstructured":"National Health Care Institute, Dutch drug database, Https:\/\/Www.Medicijnkosten.Nl. Accessed August 25 (2023)."},{"key":"10.1016\/j.ejrad.2026.113213_b0125","unstructured":"National Health Care Institute, Guideline for economic evaluations in healthcare, Diemen, 2024."},{"key":"10.1016\/j.ejrad.2026.113213_b0130","unstructured":"Statistics Netherlands, Consumer Price Index, Available Online: Https:\/\/Opendata.Cbs.Nl\/Statline\/#\/CBS\/Nl\/ (Accessed on 5 July 2025) (2024)."},{"key":"10.1016\/j.ejrad.2026.113213_b0135","unstructured":"R Core Team (2022), R: A language and environment for statistical computing, (2022)."},{"key":"10.1016\/j.ejrad.2026.113213_b0140","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41391-023-00755-2","article-title":"Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer\u2014a systematic review and meta-analysis","volume":"27","author":"Huang","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ejrad.2026.113213_b0145","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1007\/s00259-021-05620-9","article-title":"Comparing the clinical performance and cost efficacy of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in the diagnosis of recurrent prostate cancer: a Markov chain decision analysis","volume":"49","author":"Alberts","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ejrad.2026.113213_b0150","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejrad.2026.113213_b0155","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1007\/s00259-021-05403-2","article-title":"Moving the goalposts while scoring-the dilemma posed by new PET technologies","volume":"48","author":"Rogasch","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ejrad.2026.113213_b0160","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S1470-2045(24)00451-0","article-title":"Common sense oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials","volume":"26","author":"Gyawali","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejrad.2026.113213_b0165","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejrad.2026.113213_b0170","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153808","article-title":"Reliability and efficiency of the CAPRI-3 metastatic prostate cancer registry driven by artificial intelligence","volume":"15","author":"Bosch","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejrad.2026.113213_b0175","series-title":"Methods for the economic evaluation of health care programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.ejrad.2026.113213_b0180","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clgc.2021.10.008","article-title":"Symptomatic skeletal events and the use of bone health agents in a real-world treated metastatic castration resistant prostate cancer population: results from the CAPRI-Study in the Netherlands","volume":"20","author":"Kuppen","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.ejrad.2026.113213_b0185","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-025-07473-y","article-title":"Model-based cost-effectiveness studies in nuclear medicine: an unavoidable fact of life","author":"van Mossel","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ejrad.2026.113213_b0190","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40273-024-01447-y","article-title":"A Systematic literature review of modelling approaches to evaluate the cost effectiveness of PET\/CT for therapy response monitoring in oncology","volume":"43","author":"van Mossel","year":"2024","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ejrad.2026.113213_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2013.06.008","article-title":"Current methodological issues in the economic assessment of personalized medicine","volume":"16","author":"Annemans","year":"2013","journal-title":"Value Health"}],"container-title":["European Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X26005619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X26005619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:34:34Z","timestamp":1792737274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0720048X26005619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":39,"alternative-id":["S0720048X26005619"],"URL":"https:\/\/doi.org\/10.1016\/j.ejrad.2026.113213","relation":{},"ISSN":["0720-048X"],"issn-type":[{"value":"0720-048X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Laying the groundwork for future health economic evaluation of [18F]PSMA PET\/CT in guiding treatment decisions for metastatic castration-resistant prostate cancer patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejrad.2026.113213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113213"}}